公开(公告)号：US12129224B2

公开(公告)日：2024-10-29

申请号：US17435731

申请日：2020-03-05

Applicant: ITALFARMACO SPA

Inventor： Stefano Turchetta ,  Maurizio Zenoni ,  Elio Ullucci ,  Stefania Cocciolo ,  Giorgio Berardi ,  Nakia Maulucci

IPC: C07C271/28 ,  B01J20/286 ,  C07C269/06 ,  C07C269/08 ,  G01N30/02

CPC classification number: C07C271/28 ,  B01J20/286 ,  C07C269/06 ,  C07C269/08 ,  G01N2030/027 ,  C07C269/06 ,  C07C271/28 ,  C07C269/08 ,  C07C271/28

Abstract: A process for obtaining {{6-[(diethylamino)methyl]naphthalen-2-yl}methyl[4-(hydroxycarbamoyl)phenyl]carbamate and/or pharmaceutically acceptable salts thereof having high purity is described. This process allows to obtain a product having an amount of any single unknown impurity equal to or less than 0.10%, as well as a product having a purity greater than 99.5%, preferably equal to or greater than 99.6%.
An HPLC method for determining the purity of the product and possible impurities thereof is also described.

公开(公告)号：US12098116B2

公开(公告)日：2024-09-24

申请号：US18169016

申请日：2023-02-14

Applicant: United Therapeutics Corporation

Inventor： Kenneth Phares

IPC: C07C271/28

CPC classification number: C07C271/28 ,  C07B2200/13

Abstract: Described herein are crystalline forms of a prostacyclin (IP) receptor agonist compound, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist compound.

公开(公告)号：US11891655B2

公开(公告)日：2024-02-06

申请号：US17730004

申请日：2022-04-26

Applicant: Battelle Memorial Institute

Inventor： Aaron T. Wright ,  Susan Ramos-Hunter ,  Christopher Whidbey

IPC: C12Q1/68 ,  C12Q1/6837 ,  C07K1/13 ,  C12Q1/6841 ,  C12Q1/48 ,  C07D311/16 ,  C07D405/04 ,  C07C233/33 ,  C07C233/20 ,  C07C247/00 ,  G01N33/58 ,  C07C305/22 ,  C07D203/26 ,  C07C247/12 ,  C07C203/04 ,  C07C271/28 ,  C07D405/12 ,  C07H19/067 ,  C07H15/203 ,  C12Q1/34 ,  C07C317/40

CPC classification number: C12Q1/6837 ,  C07C203/04 ,  C07C233/20 ,  C07C233/33 ,  C07C247/00 ,  C07C247/12 ,  C07C271/28 ,  C07C305/22 ,  C07C317/40 ,  C07D203/26 ,  C07D311/16 ,  C07D405/04 ,  C07D405/12 ,  C07H15/203 ,  C07H19/067 ,  C07K1/13 ,  C12Q1/34 ,  C12Q1/48 ,  C12Q1/6841 ,  G01N33/582 ,  G01N33/583 ,  C12Q2565/514 ,  C12Q2600/106 ,  G01N2333/91177

Abstract: Activity-based probes that can be used to selectively identify and characterize enzymes that are involved in different phases of xenobiotic metabolism in a host and its microbiota population(s) are described. The activity-based probes described specifically label only their target active enzymes involved in xenobiotic metabolism and therefore provide a measurement of true protein functional activity rather than transcript or protein abundance. The activity-based probes also provide multimodal profiling of these active enzymes. Methods for preparing the activity based probes and exemplary methods for their use also are disclosed.

公开(公告)号：US20240002409A1

公开(公告)日：2024-01-04

申请号：US16950901

申请日：2020-11-17

Applicant: Covestro Deutschland AG

Inventor： Thomas RÖLLE ,  Horst BERNETH ,  Dennis HÖNEL ,  Friedrich-Karl BRUDER ,  Jürgen KINTRUP

IPC: C07F5/02 ,  C07C211/63 ,  C07C211/64 ,  C07C217/08 ,  C07C219/10 ,  C07C219/28 ,  C07C219/30 ,  C07C271/12 ,  C07C271/20 ,  C07C271/24 ,  C07D213/20 ,  C07D233/58 ,  C07D295/037 ,  C07D413/06 ,  C07F5/04 ,  C07F9/54 ,  G03F7/00 ,  C07C271/28 ,  C07D347/00 ,  C07D233/02 ,  C07D247/00 ,  C07D335/02 ,  C07C271/16 ,  C07D309/34

CPC classification number: C07F5/027 ,  C07C2601/14 ,  C07C211/64 ,  C07C217/08 ,  C07C219/10 ,  C07C219/28 ,  C07C219/30 ,  C07C271/12 ,  C07C271/20 ,  C07C271/24 ,  C07D213/20 ,  C07D233/58 ,  C07D295/037 ,  C07D413/06 ,  C07F5/04 ,  C07F9/5407 ,  C07F9/5442 ,  G03F7/001 ,  C07C271/28 ,  C07D347/00 ,  C07F9/54 ,  C07D233/02 ,  C07D247/00 ,  C07D335/02 ,  C07C271/16 ,  C07D309/34 ,  C07C211/63

Abstract: The invention relates to a process for preparing triaryl organo borates proceeding from organoboronic esters in the presence of an n-valent cation 1/n Kn+, comprising the anhydrous workup of the reaction mixture and the use of the triaryl organoborates obtained as co-initiator in photopolymer formulations, holographic media and holograms.

公开(公告)号：US11858900B2

公开(公告)日：2024-01-02

申请号：US17145453

申请日：2021-01-11

Applicant: OcuTerra Therapeutics, Inc.

Inventor： D. Scott Edwards ,  Ben C. Askew ,  Takeru Furuya

IPC: C07D217/04 ,  C07C233/43 ,  C07C271/28 ,  C07D209/44

CPC classification number: C07D217/04 ,  C07C233/43 ,  C07C271/28 ,  C07D209/44

Abstract: The application relates to 2-amino-4-(substituted amino)phenyl carbamate derivatives, or pharmaceutically acceptable salts or solvates thereof, as KCNQ2/3 potassium channel modulators, and methods of their uses.

公开(公告)号：US20180327351A1

公开(公告)日：2018-11-15

申请号：US15756692

申请日：2016-09-08

Applicant: CEPHALON, INC.

Inventor： Ralph LAUFER ,  Gregory R. OTT

IPC: C07C271/22 ,  C07C229/42 ,  C07C237/20 ,  C07F9/09 ,  C07C305/12 ,  C07D263/18 ,  C07K4/00 ,  C07D223/16 ,  C07D207/09 ,  C07C233/36 ,  C07C233/05 ,  C07C311/51 ,  C07C233/47 ,  C07H13/04 ,  C07C233/54 ,  C07C271/28 ,  A61K31/198 ,  A61K31/325 ,  A61K31/196 ,  A61K31/661 ,  A61K31/255 ,  A61K31/421 ,  A61K38/03 ,  A61K31/216 ,  A61K31/24 ,  A61K31/55 ,  A61K31/40 ,  A61K31/165 ,  A61K31/18 ,  A61K31/7028

CPC classification number: C07C271/22 ,  A61K31/165 ,  A61K31/18 ,  A61K31/196 ,  A61K31/198 ,  A61K31/216 ,  A61K31/24 ,  A61K31/255 ,  A61K31/325 ,  A61K31/40 ,  A61K31/421 ,  A61K31/55 ,  A61K31/661 ,  A61K31/7028 ,  A61K38/03 ,  C07C229/42 ,  C07C233/05 ,  C07C233/36 ,  C07C233/47 ,  C07C233/51 ,  C07C233/54 ,  C07C237/20 ,  C07C271/28 ,  C07C305/12 ,  C07C311/51 ,  C07D207/08 ,  C07D207/09 ,  C07D223/12 ,  C07D223/16 ,  C07D263/18 ,  C07F9/09 ,  C07H13/04 ,  C07K4/00

Abstract: The present disclosure relates to prodrugs of 7-chlorokynurenic acid. In certain embodiments, the prodrugs include those having the structure of any one of formula (I)-(VIII), wherein R1-R13, monomer 1, monomer 2, and linker are defined herein. Also provided are methods of preparing and using these prodrugs.

公开(公告)号：US10040754B2

公开(公告)日：2018-08-07

申请号：US14835165

申请日：2015-08-25

Applicant: FUJIFILM Corporation

Inventor： Hiroshi Inada ,  Naozumi Shiraiwa ,  Yingjie Xu ,  Aiko Yoshida ,  Masaki Noro ,  Yasukazu Kuwayama ,  Nobutaka Fukagawa

IPC: C07C271/20 ,  C07C271/06 ,  C07C271/28 ,  C07C271/36 ,  C07C271/56 ,  C07D295/20 ,  C08J5/18 ,  C08K5/16 ,  G02B1/14 ,  G02B5/30

CPC classification number: C07C271/20 ,  B32B2457/202 ,  C07C271/06 ,  C07C271/28 ,  C07C271/36 ,  C07C271/56 ,  C07D295/20 ,  C08J5/18 ,  C08J2301/10 ,  C08J2301/12 ,  C08K5/16 ,  C08K5/205 ,  G02B1/14 ,  G02B5/30 ,  Y10T428/1041 ,  Y10T428/31971 ,  C08L1/10

Abstract: A cellulose acylate film, which includes a compound denoted by general formula (I) below, the equivalent U of which, calculated as a value obtained by dividing the molecular weight of the compound by the number of divalent linking groups denoted by —O—C(═O)—NH— contained per molecule, is less than or equal to 515, wherein, in general formula (I), each of L11 and L21 independently denotes an optionally substituted alkylene group; each of L12 and L22 independently denotes a single bond, any one of or any combination of —O—, —NR1—, —S— and —C(═O)—; R1 denotes a hydrogen atom or a substituent; each of n1 and n2 independently denotes an integer of 0 to 20, with at least either n1 or n2 being an integer of greater than or equal to 1. Q1-(L12-L11)n1-O—C(═O)—NH-(L21-L22)n2-Q2  General formula (I)

公开(公告)号：US09956551B2

公开(公告)日：2018-05-01

申请号：US15158238

申请日：2016-05-18

Applicant: Bruce H. Lipshutz ,  Sachin Handa

Inventor： Bruce H. Lipshutz ,  Sachin Handa

IPC: C07C45/68 ,  C07C41/30 ,  C07C209/32 ,  C07B37/04 ,  B01J31/06 ,  B01J35/00 ,  B01J35/12 ,  B01J31/02 ,  B01J23/89 ,  B01J37/16 ,  C07F9/12 ,  C07D471/04 ,  C07D409/04 ,  C07D405/14 ,  C07D405/04 ,  C07D403/04 ,  C07D401/04 ,  C07D333/60 ,  C07D317/22 ,  C07D317/46 ,  C07D241/18 ,  C07D239/26 ,  C07D239/54 ,  B01J31/24 ,  B01J31/22 ,  C07C201/12 ,  C07D211/70 ,  C07D213/30 ,  C07D213/64 ,  C07D215/06 ,  C07C269/08 ,  C07C209/68

CPC classification number: B01J31/2404 ,  B01J23/8906 ,  B01J31/0202 ,  B01J31/0209 ,  B01J31/068 ,  B01J31/22 ,  B01J35/0013 ,  B01J35/10 ,  B01J35/12 ,  B01J37/16 ,  B01J2231/4211 ,  B01J2231/4227 ,  B01J2231/4266 ,  B01J2231/64 ,  B01J2531/004 ,  B01J2531/007 ,  B01J2531/824 ,  B01J2531/842 ,  B01J2531/96 ,  B01J2531/985 ,  C07B37/04 ,  C07C37/18 ,  C07C41/30 ,  C07C45/68 ,  C07C201/12 ,  C07C205/12 ,  C07C209/325 ,  C07C209/68 ,  C07C211/45 ,  C07C269/06 ,  C07C269/08 ,  C07C319/20 ,  C07C2603/24 ,  C07D211/70 ,  C07D213/30 ,  C07D213/64 ,  C07D215/06 ,  C07D239/26 ,  C07D239/54 ,  C07D241/18 ,  C07D317/22 ,  C07D317/46 ,  C07D333/60 ,  C07D401/04 ,  C07D403/04 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D471/04 ,  C07F9/12 ,  C07C271/28 ,  C07C321/28 ,  C07C43/215 ,  C07C43/205 ,  C07C43/2055 ,  C07C47/546 ,  C07C47/575 ,  C07C39/21

Abstract: In one embodiment, the present application discloses a catalyst composition comprising: a) a reaction solvent or a reaction medium; b) organometallic nanoparticles comprising: i) a nanoparticle (NP) catalyst, prepared by a reduction of an iron salt in an organic solvent, wherein the catalyst comprises at least one other metal selected from the group consisting of Pd, Pt, Au, Ni, Co, Cu, Mn, Rh, Ir, Ru and Os or mixtures thereof; c) a ligand; and d) a surfactant; wherein the metal or mixtures thereof is present in less than or equal to 50,000 ppm relative to the iron salt.

公开(公告)号：US20180105505A1

公开(公告)日：2018-04-19

申请号：US15573183

申请日：2016-05-12

Applicant: GEORGETOWN UNIVERSITY

Inventor： Milton L. Brown ,  Yali Kong ,  Jacqueline Smith ,  Kan Wang ,  Shujie Hou

IPC: C07D311/02 ,  C07C271/28 ,  C07C321/14 ,  C07C69/017 ,  C07C69/003 ,  A61K47/69 ,  A61P35/00 ,  G01N21/64

CPC classification number: C07D311/02 ,  A61K31/352 ,  A61K47/6957 ,  A61P35/00 ,  C07C69/003 ,  C07C69/017 ,  C07C271/28 ,  C07C321/14 ,  C07D311/18 ,  C07D311/58 ,  G01N21/64

Abstract: A glutathione-cleavable prodrug is provided herein, as well as methods for its use in treating cancer, including triple negative breast cancer. The prodrug can be cleaved by glutathione under physiological conditions to generate a biologically active agent. The compound described herein is advantageous as the compound is fluorescent and can therefore be monitored within a subject.

公开(公告)号：US09944604B2

公开(公告)日：2018-04-17

申请号：US13456880

申请日：2012-04-26

Applicant: Ulrich Görgens ,  Akihiko Yanagi ,  Kazue Yanagi ,  Keisuke Yanagi ,  Kasumi Yanagi ,  Katsuaki Wada ,  Tetsuya Murata ,  Yukiyoshi Watanabe ,  Jun Mihara ,  Koichi Araki

Inventor： Ulrich Görgens ,  Akihiko Yanagi ,  Katsuaki Wada ,  Tetsuya Murata ,  Yukiyoshi Watanabe ,  Jun Mihara ,  Koichi Araki

IPC: A61K31/33 ,  C07D213/60 ,  A01N37/46 ,  A01N43/08 ,  A01N43/10 ,  A01N43/40 ,  A01N43/56 ,  A01N43/82 ,  A01N47/20 ,  C07C237/42 ,  C07C271/28 ,  C07C317/44 ,  C07C323/62

CPC classification number: C07D213/60 ,  A01N37/46 ,  A01N43/08 ,  A01N43/10 ,  A01N43/40 ,  A01N43/56 ,  A01N43/82 ,  A01N47/20 ,  C07C237/42 ,  C07C271/28 ,  C07C317/44 ,  C07C323/62 ,  C07C2601/10 ,  C07C2601/16

Abstract: The invention relates to a composition comprising at least one aminobenzamide compound or a salt thereof for controlling animal parasites, veterinary pharmaceutical compositions comprising at least one aminobenzamide of formula (I) for preventing infection with diseases transmitted through parasites, its use for the preparation of a veterinary pharmaceutical for controlling animal parasites, and a method for preventing infection with diseases transmitted through parasites.